HF
CABA icon

HRT Financial’s Cabaletta Bio CABA Stock Holding History

HRT Financial’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$264K Buy
+98,500
New +$274K ﹤0.01% 2979

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HRT Financial's CABA Position: Q1 2026 in Review

HRT Financial opened a new position in Cabaletta Bio (CABA) in Q1 2026: 33,104 shares worth $89K. The stake represents ﹤0.01% of the portfolio and ranks #3369 among its holdings. This is a return to the name: HRT Financial previously reported a position in CABA as recently as Q2 2025.

HRT Financial first reported a position in CABA in Q2 2021 and has held it in 7 quarters since. The position peaked at $828K in Q1 2023. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

  • HRT Financial held 33,104 shares of Cabaletta Bio worth $89K as of Q1 2026.
  • Cabaletta Bio was a new HRT Financial position in Q1 2026.
  • Cabaletta Bio made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3369 holding.
  • HRT Financial first reported a position in Cabaletta Bio in Q2 2021 and has held it in 7 quarters since.
  • HRT Financial's Cabaletta Bio position peaked at $828K in Q1 2023.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.